Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1993 June; 67(6): 1163–1170.
PMCID: PMC1968495

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.


SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide, WIN 59075, tirapazamine) is the lead compound in a new class of bioreductive anticancer drugs, the benzotriazine di-N-oxides. It is currently undergoing Phase I clinical testing. The preferential tumour cell killing of SR 4233 is a result of its high specific toxicity to cells at low oxygen tensions. Such hypoxic cells are a common feature of solid tumours, but not normal tissues, and are resistant to cancer therapies including radiation and some anticancer drugs. The killing of these tumour cells by SR 4233, particularly when given on multiple occasions, can increase total tumour cell killing by fractionated irradiation by several orders of magnitude without increasing toxicity to surrounding normal tissues. Topics covered in this review include the rationale for developing a hypoxic cytotoxic agent, the cytotoxicity of SR 4233 as a function of oxygen concentration, the mechanism of action of the drug and its intracellular target and the in vivo evidence that the drug may be useful as an adjunct both to radiotherapy and chemotherapy. Finally, the major unanswered questions on the drug are outlined.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.9M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Adams GE. Hypoxia-mediated drugs for radiation and chemotherapy. Cancer. 1981 Aug 1;48(3):696–707. [PubMed]
  • Adams GE, Stratford IJ, Edwards HS, Bremner JC, Cole S. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9. Int J Radiat Oncol Biol Phys. 1992;22(4):717–720. [PubMed]
  • Baker MA, Zeman EM, Hirst VK, Brown JM. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 1988 Nov 1;48(21):5947–5952. [PubMed]
  • Bedford JS, Goodhead DT. Breakage of human interphase chromosomes by alpha particles and X-rays. Int J Radiat Biol. 1989 Feb;55(2):211–216. [PubMed]
  • Biedermann KA, Wang J, Graham RP, Brown JM. SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br J Cancer. 1991 Mar;63(3):358–362. [PMC free article] [PubMed]
  • Bremner JC, Stratford IJ, Bowler J, Adams GE. Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer. 1990 May;61(5):717–721. [PMC free article] [PubMed]
  • Brown JM. Keynote address: hypoxic cell radiosensitizers: where next? Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):987–993. [PubMed]
  • Brown JM, Koong A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J Natl Cancer Inst. 1991 Feb 6;83(3):178–185. [PubMed]
  • Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 1990 Dec 15;50(24):7745–7749. [PubMed]
  • Brown JM, Lemmon MJ. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother Oncol. 1991;20 (Suppl 1):151–156. [PubMed]
  • Brown JM, Lemmon MJ. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):457–461. [PubMed]
  • Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, Pringle JF. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl. 1978 Jun;3:302–306. [PubMed]
  • Cahill A, White IN. Reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcinogenesis. 1990 Aug;11(8):1407–1411. [PubMed]
  • CATER DB, GRIGSON CM, WATKINSON DA. Changes of oxygen tension in tumours induced by vasoconstrictor and vasodilator drugs. Acta radiol. 1962 Dec;58:401–434. [PubMed]
  • Chaplin DJ, Acker B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):579–585. [PubMed]
  • Chaplin DJ, Horsman MR, Aoki DS. Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br J Cancer. 1991 Jan;63(1):109–113. [PMC free article] [PubMed]
  • Cornforth MN, Bedford JS. A quantitative comparison of potentially lethal damage repair and the rejoining of interphase chromosome breaks in low passage normal human fibroblasts. Radiat Res. 1987 Sep;111(3):385–405. [PubMed]
  • Costa AK, Baker MA, Brown JM, Trudell JR. In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumor agent. Cancer Res. 1989 Feb 15;49(4):925–929. [PubMed]
  • Fracasso PM, Sartorelli AC. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. Cancer Res. 1986 Aug;46(8):3939–3944. [PubMed]
  • Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988 May;14(5):831–838. [PubMed]
  • Henk JM, Smith CW. Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial. Lancet. 1977 Jul 16;2(8029):104–105. [PubMed]
  • Höckel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res. 1991 Nov 15;51(22):6098–6102. [PubMed]
  • Holden SA, Teicher BA, Ara G, Herman TS, Coleman CN. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst. 1992 Feb 5;84(3):187–193. [PubMed]
  • Jenkins TC, Naylor MA, O'Neill P, Threadgill MD, Cole S, Stratford IJ, Adams GE, Fielden EM, Suto MJ, Stier MA. Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem. 1990 Sep;33(9):2603–2610. [PubMed]
  • Kennedy KA. Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des. 1987 Oct;2(2):181–194. [PubMed]
  • Keohane A, Godden J, Stratford IJ, Adams GE. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation. Br J Cancer. 1990 May;61(5):722–726. [PMC free article] [PubMed]
  • Kjellen E, Joiner MC, Collier JM, Johns H, Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol. 1991 Oct;22(2):81–91. [PubMed]
  • Koch CJ. A thin-film culturing technique allowing rapid gas-liquid equilibration (6 sec) with no toxicity to mammalian cells. Radiat Res. 1984 Feb;97(2):434–442. [PubMed]
  • Laderoute K, Wardman P, Rauth AM. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233). Biochem Pharmacol. 1988 Apr 15;37(8):1487–1495. [PubMed]
  • Lin AJ, Cosby LA, Shansky CW, Sartorelli AC. Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. J Med Chem. 1972 Dec;15(12):1247–1252. [PubMed]
  • Lloyd RV, Duling DR, Rumyantseva GV, Mason RP, Bridson PK. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol. 1991 Sep;40(3):440–445. [PubMed]
  • Marshall RS, Rauth AM. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant. Cancer Res. 1986 Jun;46(6):2709–2713. [PubMed]
  • Moore HW. Bioactivation as a model for drug design bioreductive alkylation. Science. 1977 Aug 5;197(4303):527–532. [PubMed]
  • Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev. 1987;5(4):313–341. [PubMed]
  • Mueller-Klieser W, Vaupel P, Manz R, Schmidseder R. Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int J Radiat Oncol Biol Phys. 1981 Oct;7(10):1397–1404. [PubMed]
  • Mulcahy RT. Effect of oxygen on misonidazole chemosensitization and cytotoxicity in vitro. Cancer Res. 1984 Oct;44(10):4409–4413. [PubMed]
  • Overgaard J, Hansen HS, Jørgensen K, Hjelm Hansen M. Primary radiotherapy of larynx and pharynx carcinoma--an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):515–521. [PubMed]
  • Prise KM, Davies S, Michael BD. The relationship between radiation-induced DNA double-strand breaks and cell kill in hamster V79 fibroblasts irradiated with 250 kVp X-rays, 2.3 MeV neutrons or 238Pu alpha-particles. Int J Radiat Biol Relat Stud Phys Chem Med. 1987 Dec;52(6):893–902. [PubMed]
  • Rockwell S, Kennedy KA. Combination therapy with radiation and mitomycin C: preliminary results with EMT6 tumor cells in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1979 Sep;5(9):1673–1676. [PubMed]
  • Rockwell S, Kennedy KA, Sartorelli AC. Mitomycin-C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):753–755. [PubMed]
  • Rockwell S, Moulder JE. Hypoxic fractions of human tumors xenografted into mice: a review. Int J Radiat Oncol Biol Phys. 1990 Jul;19(1):197–202. [PubMed]
  • Roizin-Towle L, Pirro JP, Hall EJ. Studies with bifunctional bioreductive drugs. II. Cytotoxicity assayed with A-549 lung carcinoma cells of human origin. Radiat Res. 1990 Oct;124(1 Suppl):S50–S55. [PubMed]
  • Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res. 1988 Feb 15;48(4):775–778. [PubMed]
  • Siemann DW. Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1585–1594. [PubMed]
  • Spiegel JF, Spear MA, Brown JM. Toxicology of daily administration to mice of the radiation potentiator SR 4233 (WIN 59075). Radiother Oncol. 1993 Jan;26(1):79–81. [PubMed]
  • Stratford IJ, Stephens MA. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):973–976. [PubMed]
  • Stratford IJ, O'Neill P, Sheldon PW, Silver AR, Walling JM, Adams GE. RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol. 1986 Jan 1;35(1):105–109. [PubMed]
  • Sun JR, Brown JM. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Res. 1989 Oct 15;49(20):5664–5670. [PubMed]
  • Tannock I, Guttman P. Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer. 1981 Feb;43(2):245–248. [PMC free article] [PubMed]
  • Tannock IF. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. Br J Cancer. 1980 Dec;42(6):861–870. [PMC free article] [PubMed]
  • Taylor YC, Evans JW, Brown JM. Mechanism of sensitization of Chinese hamster ovary cells to melphalan by hypoxic treatment with misonidazole. Cancer Res. 1983 Jul;43(7):3175–3181. [PubMed]
  • Taylor YC, Rauth AM. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res. 1978 Sep;38(9):2745–2752. [PubMed]
  • Vaupel P, Schlenger K, Knoop C, Höckel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 1991 Jun 15;51(12):3316–3322. [PubMed]
  • Voorhees WD, 3rd, Babbs CF. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur J Cancer Clin Oncol. 1982 Oct;18(10):1027–1033. [PubMed]
  • Walton MI, Wolf CR, Workman P. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol. 1992 Jul 22;44(2):251–259. [PubMed]
  • Walton MI, Workman P. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol. 1990 Jun 1;39(11):1735–1742. [PubMed]
  • Wang J, Biedermann KA, Brown JM. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 1992 Aug 15;52(16):4473–4477. [PubMed]
  • Wang J, Biedermann KA, Wolf CR, Brown JM. Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. Br J Cancer. 1993 Feb;67(2):321–325. [PMC free article] [PubMed]
  • Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R, Rockwell S, Sartorelli AC, Fischer JJ. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):3–9. [PubMed]
  • Zeman EM, Brown JM. Pre- and post-irradiation radiosensitization by SR 4233. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):967–971. [PubMed]
  • Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1239–1242. [PubMed]
  • Zeman EM, Hirst VK, Lemmon MJ, Brown JM. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol. 1988 Jul;12(3):209–218. [PubMed]
  • Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst. 1989 Jul 5;81(13):1005–1013. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK